Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2024  > 
Guo Fansheng, Zeng Qiang, Dou Jian. Hepatitis E virus infection in liver transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2023216
Citation: Guo Fansheng, Zeng Qiang, Dou Jian. Hepatitis E virus infection in liver transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2023216
shu

Hepatitis E virus infection in liver transplant recipients

doi: 10.3969/j.issn.1674-7445.2023216

  • Department of Hepatobiliary Surgery, Hebei Medical University Third Hospital, Shijiazhuang 050051, China

More Information
  • Corresponding author: Dou Jian, Email: 2423978344@qq.com
  • Received Date: 2023-10-23
  • Accepted Date: 2024-01-18
    • Available Online: 2024-02-29
    Abstract
  • Hepatitis E virus infection is a common cause of acute viral hepatitis. In recent years, the incidence of hepatitis E has shown an increasing trend, which has gradually become an important cause of acute viral hepatitis worldwide. Age, sex, intensity of immunosuppression and socio-economic factors are all risk factors for hepatitis E virus infection. Liver transplant recipients require long-term use of immunosuppressive drugs for anti rejection treatment, prone to hepatitis E virus infection and at the risk of liver fibrosis and cirrhosis due to immunosuppression status. Therefore, special attention should be paid to liver transplant recipients in clinical practice. Meantime, related risk factors should be identified to assist diagnosis and take stricter preventive measures. According to literature review, the etiological characteristics of hepatitis E virus and the epidemiological characteristics, clinical manifestations, diagnosis and treatment of hepatitis E virus infection in liver transplant recipients were reviewed, aiming to properly monitor, treat and prevent hepatitis E virus infection in liver transplant recipients in clinical practice, improving the prognosis of liver transplant recipients.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    中华医学会肝病学分会. 戊型肝炎防治共识[J]. 中华肝脏病杂志, 2022, 30(8): 820-831. DOI: 10.3760/cma.j.cn501113-20220729-00401.

    Chinese Society of Hepatology. Consensus on prevention and treatment of hepatitis E[J]. Chin J Hepatol, 2022, 30(8): 820-831. DOI: 10.3760/cma.j.cn501113-20220729-00401.
    [2]
    CARTER M, SOLSRUD K, YEDDULA S, et al. Hepatitis E diagnosis and management after liver, kidney, or heart transplant: a single-center experience[J]. Transplant Proc, 2022, 54(7): 1737-1741. DOI: 10.1016/j.transproceed.2022.04.025.
    [3]
    TAKAKUSAGI S, KAKIZAKI S, TAKAGI H. The diagnosis, pathophysiology, and treatment of chronic hepatitis E virus infection-a condition affecting immunocompromised patients[J]. Microorganisms, 2023, 11(5): 1303. DOI: 10.3390/microorganisms 11051303.
    [4]
    ZHOU Y, ZHAO C, TIAN Y, et al. Characteristics and functions of HEV proteins[J]. Adv Exp Med Biol, 2023, 1417: 15-32. DOI: 10.1007/978-981-99-1304-6_2.
    [5]
    LIU X, WANG M, YIN X. Cellular organelles involved in hepatitis E virus infection[J]. Pathogens, 2021, 10(9): 1206. DOI: 10.3390/pathogens10091206.
    [6]
    WANG B, MAHSOUB HM, LI W, et al. Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model[J]. mBio, 2023, 14(2): e0337222. DOI: 10.1128/mbio.03372-22.
    [7]
    DING Q, HELLER B, CAPUCCINO JM, et al. Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles[J]. Proc Natl Acad Sci U S A, 2017, 114(5): 1147-1152. DOI: 10.1073/pnas.1614955114.
    [8]
    PEZZONI G, STERCOLI L, PEGOIANI E, et al. Antigenic characterization of ORF2 and ORF3 proteins of hepatitis E Virus (HEV)[J]. Viruses, 2021, 13(7): 1385. DOI: 10.3390/v13071385.
    [9]
    李云龙, 黄芬. 戊型肝炎病毒跨种间传播研究进展[J]. 临床肝胆病杂志, 2023, 39(11): 2538-2542.

    LI YL, HUANG F. Research advances in the interspecies transmission of hepatitis E virus[J]. J Clin Hepatol, 2023, 39(11): 2538-2542.
    [10]
    高文光. 人畜共患性戊型肝炎病毒[J]. 中国畜牧业, 2023(16): 85-86.

    GAO WG. Zoonotic hepatitis E virus[J]. China Anim Ind, 2023(16): 85-86.
    [11]
    徐孟, 吴珂, 伍智勇等. 戊型肝炎病毒基因分型研究进展[J]. 中国病毒病杂志, 2022, 12(2): 138-143. DOI: 10.16505/j.2095-0136.2022.0020.

    XU M, WU K, WU ZY, et al. Research progress in genotyping of hepatitis E virus[J]. Chin J Viral Dis, 2022, 12(2): 138-143. DOI: 10.16505/j.2095-0136.2022.0020.
    [12]
    SRIDHAR S, YIP CC, WU S, et al. Transmission of rat hepatitis E virus infection to humans in Hong Kong: a clinical and epidemiological analysis[J]. Hepatology, 2021, 73(1): 10-22. DOI: 10.1002/hep.31138.
    [13]
    SRIDHAR S, YIP CCY, LO KHY, et al. Hepatitis E virus species C infection in humans, Hong Kong[J]. Clin Infect Dis, 2022, 75(2): 288-296. DOI: 10.1093/cid/ciab919.
    [14]
    VELAVAN TP, PALLERLA SR, JOHNE R, et al. Hepatitis E: an update on one health and clinical medicine[J]. Liver Int, 2021, 41(7): 1462-1473. DOI: 10.1111/liv.14912.
    [15]
    AHMAD T, NASIR S, MUSA TH, et al. Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus[J]. Hum Vaccin Immunother, 2021, 17(3): 857-871. DOI: 10.1080/21645515.2020.1795458.
    [16]
    FERNÁNDEZ VILLALOBOS NV, KESSEL B, TORRES PÁEZ JC, et al. Seroprevalence of Hepatitis E virus in children and adolescents living in urban Bogotá: an explorative cross-sectional study[J]. Front Public Health, 2023, 11: 981172. DOI: 10.3389/fpubh.2023.981172.
    [17]
    NELSON KE, LABRIQUE AB, KMUSH BL. Epidemiology of genotype 1 and 2 hepatitis E virus infections[J]. Cold Spring Harb Perspect Med, 2019, 9(6): a031732. DOI: 10.1101/cshperspect.a031732.
    [18]
    LU J, LI Q, JIANG J, et al. Laboratory-based surveillance and clinical profile of sporadic HEV infection in Shanghai, China[J]. Virol Sin, 2021, 36(4): 644-654. DOI: 10.1007/s12250-020-00336-w.
    [19]
    疾病预防控制局. 2019年全国法定传染病疫情概况[EB/OL]. [2023-12-01]. http://www.nhc.gov.cn/jkj/s6873/202004/b1519e1bc1a944fc8ec176db600f68d1.shtml .
    [20]
    REN X, WU P, WANG L, et al. Changing epidemiology of hepatitis A and hepatitis e viruses in China, 1990-2014[J]. Emerg Infect Dis, 2017, 23(2): 276-279. DOI: 10.3201/2302.161095.
    [21]
    MARKAKIS GE, PAPATHEODORIDIS GV, CHOLONGITAS E. Epidemiology and treatment of hepatitis E in the liver transplantation setting: a literature review[J]. J Viral Hepat, 2022, 29(9): 698-718. DOI: 10.1111/jvh.13709.
    [22]
    KOMOLMIT P, ORANRAP V, SUKSAWATAMNUAY S, et al. Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study[J]. Sci Rep, 2020, 10(1): 7352. DOI: 10.1038/s41598-020-64551-x.
    [23]
    DARSTEIN F, HÄUSER F, STRAUB BK, et al. Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: a real-world cohort[J]. Clin Transplant, 2018, 32(11): e13411. DOI: 10.1111/ctr.13411.
    [24]
    CARMO J, MARQUES S, MATEUS É, et al. Ribavirin for chronic hepatitis E in liver-transplant setting: a safe and highly effective therapy[J]. J Clin Gastroenterol, 2016, 50(7): 608. DOI: 10.1097/MCG.0000000000000554.
    [25]
    刘淼. 戊型肝炎病毒与血液安全的研究进展[J]. 中国输血杂志, 2023, 36(4): 359-364. DOI: 10.13303/j.cjbt.issn.1004-549x.2023.04.017.

    LIU M. Research progress on hepatitis E virus and blood safety[J]. Chin J Blood Transfus, 2023, 36(4): 359-364. DOI: 10.13303/j.cjbt.issn.1004-549x.2023.04.017.
    [26]
    FRANKAL M, SKOGLUND C, CASTEDAL M, et al. Hepatitis E virus infection, a risk for liver transplant recipients in Sweden[J]. Transplant Direct, 2022, 8(12): e1409. DOI: 10.1097/TXD.0000000000001409.
    [27]
    SRIDHAR S, CHENG VCC, WONG SC, et al. Donor-derived genotype 4 hepatitis E virus infection, Hong Kong, China, 2018[J]. Emerg Infect Dis, 2019, 25(3): 425-433. DOI: 10.3201/eid2503.181563.
    [28]
    SCHLOSSER B, STEIN A, NEUHAUS R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient[J]. J Hepatol, 2012, 56(2): 500-502. DOI: 10.1016/j.jhep.2011.06.021.
    [29]
    REEKIE I, IRISH D, IJAZ S, et al. Hepatitis E infection in stem cell and solid organ transplantpatients: a cross-sectional study: the importance of HEV RNA screening in peri-transplant period[J]. J Clin Virol, 2018, 107: 1-5. DOI: 10.1016/j.jcv.2018.07.011.
    [30]
    ÖĞÜT S, SAYINER AA, OTLU B, et al. Hepatitis E infection in solid organ transplant recipients in Turkey[J]. Turk J Gastroenterol, 2022, 33(1): 68-73. DOI: 10.5152/tjg.2021.21071.
    [31]
    MRZLJAK A, DINJAR-KUJUNDZIC P, VILIBIC-CAVLEK T, et al. Hepatitis E seroprevalence and associated risk factors in Croatian liver transplant recipients[J]. Rev Soc Bras Med Trop, 2019, 52: e20190302. DOI: 10.1590/0037-8682-0302-2019.
    [32]
    ANKCORN MJ, IJAZ S, POH J, et al. Toward systematic screening for persistent hepatitis E virus infections in transplant patients[J]. Transplantation, 2018, 102(7): 1139-1147. DOI: 10.1097/TP.000000000 0002097.
    [33]
    DONG R, CHANG D, LUO Z, et al. The burden of HEV-related acute liver failure in Bangladesh, China and India: a systematic review and meta-analysis[J]. BMC Public Health, 2023, 23(1): 2369. DOI: 10.1186/s12889-023-17302-2.
    [34]
    FANG L, ZHANG J, CHEN H, et al. Epidemiological characteristics and clinical manifestations of hepatitis E in a tertiary hospital in China: a retrospective study[J]. Front Microbiol, 2022, 12: 831968. DOI: 10.3389/fmicb.2021.831968.
    [35]
    Centers for Disease Control and Prevention (CDC). Hepatitis E among U. S. travelers, 1989-1992[J]. MMWR Morb Mortal Wkly Rep, 1993, 42(1): 1-4.
    [36]
    WU J, XIANG Z, ZHU C, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms[J]. J Infect, 2021, 83(3): 298-305. DOI: 10.1016/j.jinf.2021.07.021.
    [37]
    ZHANG H, RAO H, WANG Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection[J]. J Gastroenterol Hepatol, 2019, 34(2): 458-465. DOI: 10.1111/jgh.14405.
    [38]
    KHUROO MS, KHUROO MS, KHUROO NS. Hepatitis E: discovery, global impact, control and cure[J]. World J Gastroenterol, 2016, 22(31): 7030-7045. DOI: 10.3748/wjg.v22.i31.7030.
    [39]
    PISCHKE S, SUNEETHA PV, BAECHLEIN C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients[J]. Liver Transpl, 2010, 16(1): 74-82. DOI: 10.1002/lt.21958.
    [40]
    SOOTHILL G, HESSEY S, EROTOCRITOU M, et al. Diagnostic utility of hepatitis E virus antigen-specific ELISA versus PCR testing in a cohort of post liver transplant patients in a large university hospital[J]. J Clin Virol, 2018, 106: 44-48. DOI: 10.1016/j.jcv.2018.07.007.
    [41]
    KAMAR N, SELVES J, MANSUY JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients[J]. N Engl J Med, 2008, 358(8): 811-817. DOI: 10.1056/NEJMoa0706992.
    [42]
    HILLEBRANDT KH, ARSENIC R, HOFMANN J, et al. Acute graft dysfunction 17 years after liver transplant: a challenging clinical and histologic manifestation of hepatitis E[J]. Exp Clin Transplant, 2018, 16(3): 348-351. DOI: 10.6002/ect.2015.0343.
    [43]
    European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection[J]. J Hepatol, 2018, 68(6): 1256-1271. DOI: 10.1016/j.jhep.2018.03.005.
    [44]
    KAMAR N, ABRAVANEL F, BEHRENDT P, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study[J]. Clin Infect Dis, 2020, 71(5): 1204-1211. DOI: 10.1093/cid/ciz953.
    [45]
    HUI W, WEI L. Treatment of hepatitis E[J]. Adv Exp Med Biol, 2023, 1417: 215-226. DOI: 10.1007/978-981-99-1304-6_15.
    [46]
    KAMAR N, ABRAVANEL F, GARROUSTE C, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient[J]. Nephrol Dial Transplant, 2010, 25(8): 2792-2795. DOI: 10.1093/ndt/gfq282.
    [47]
    CORNBERG M, PISCHKE S, MÜLLER T, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study[J]. J Hepatol, 2020, 73(3): 696-699. DOI: 10.1016/j.jhep.2020.05.020.
    [48]
    TSAREV SA, TSAREVA TS, EMERSON SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E[J]. Proc Natl Acad Sci U S A, 1994, 91(21): 10198-10202. DOI: 10.1073/pnas.91.21.10198.
    [49]
    ZHU FC, ZHANG J, ZHANG XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial[J]. Lancet, 2010, 376(9744): 895-902. DOI: 10.1016/S0140-6736(10)61030-6.
    [50]
    YU XY, CHEN ZP, WANG SY, et al. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years[J]. Vaccine, 2019, 37(32): 4581-4586. DOI: 10.1016/j.vaccine.2019.04.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (23) PDF downloads(5) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return